Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6XZF7

UPID:
DNMBP_HUMAN

ALTERNATIVE NAMES:
Scaffold protein Tuba

ALTERNATIVE UPACC:
Q6XZF7; Q8IVY3; Q9Y2L3

BACKGROUND:
Scaffold protein Tuba, or Dynamin-binding protein, is integral to several intracellular processes, including the regulation of apical junctions and normal epithelial cell cyst lumenogenesis. Its role as a guanine nucleotide exchange factor for CDC42 underscores its importance in cytoskeletal organization and possibly in membrane trafficking and ciliogenesis.

THERAPEUTIC SIGNIFICANCE:
Given its association with Cataract 48, an autosomal recessive form of cataract with early onset, the therapeutic potential of targeting Dynamin-binding protein in eye diseases is significant. Exploring this protein's functions could lead to innovative treatments for cataracts and improve visual health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.